Condition: Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Sponsor: BeOne Medicines
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.
This description comes directly from the study's public registry record.
BeOne Medicines · 1-877-828-5568 · clinicaltrials@beonemed.com
Always discuss trial participation with your own doctor first.
| Ironwood Cancer and Research Centers Chandler Ii | Chandler, Arizona, United States | Recruiting |
| Cancer and Blood Specialty Clinic | Los Alamitos, California, United States | Recruiting |
| UC Health Cancer Care and Hematology Clinic Memorial Hospital Central | Colorado Springs, Colorado, United States | Recruiting |
| Bioresearch Partners Holding Hialeah Hospital | Hialeah, Florida, United States | Recruiting |
| Orlando Health Cancer Institute Downtown Orlando | Orlando, Florida, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Hope and Healing Cancer Services | Hinsdale, Illinois, United States | Recruiting |
| University of Kansas Medical Center Research Institute | Kansas City, Kansas, United States | Recruiting |
| New England Cancer Specialists | Westbrook, Maine, United States | Recruiting |
| St Louis Cancer Care, Llp | Bridgeton, Missouri, United States | Recruiting |
| Nebraska Hematology Oncology | Lincoln, Nebraska, United States | Recruiting |
| Comprehensive Cancer Centers of Nevada | Las Vegas, Nevada, United States | Recruiting |
+ 83 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07043400